Table 2.
Results of regression analysis for primary outcome: COVID-19 severity (N = 8759)
| Characteristics | Multivariable AOR (95% CI) |
|---|---|
| Study populations (ref = Patients with nonrecently treated B-lymphoid malignancies) | |
| Nonrecently treated control population | 1.16 (0.90–1.49) |
| Recently treated control population | 0.75 (0.61–0.93) |
| Patients recently treated for B-lymphoid malignancies | 2.30 (1.58–3.36) |
| Cancer status (ref = remission/NED) | |
| Active, stable/responding | 0.86 (0.70–1.06) |
| Active, progressing | 2.67 (2.05–3.48) |
| Unknown | 1.41 (1.10–1.81) |
| Age (every 10-year increase) | 1.29 (1.24–1.35) |
| Sex (ref = Female) | |
| Male | 1.38 (1.23–1.54) |
| ECOG Performance Status (ref = zero) | |
| One Two or greater Unknown | 1.80 (1.56–2.08) 3.89 (3.27–4.63) 1.73 (1.50–2.00) |
| Smoking status (ref = never) | |
| Current or former | 1.20 (1.07–1.34) |
| Modified Charlson Comorbidity Index | 1.18 (1.13–1.22) |
| Trimester of COVID-19 diagnosis (ref = January 2020–April 2020) | |
| May 2020–Aug 2020 | 0.54 (0.47–0.62) |
| Sep 2020–Dec 2020 | 0.46 (0.39–0.55) |
| Jan 2021–Apr 2021 | 0.42 (0.35–0.50) |
| May 2021–Jun 2021 | 0.82 (0.43–1.56) |
| Race (ref = non-Hispanic white) | |
| Hispanic | 1.41 (1.20–1.67) |
| Non-Hispanic Black | 1.53 (1.33–1.76) |
| Other | 1.19 (0.96–1.47) |
| Obesity (ref = not obese) | |
| Obese | 1.19 (1.06–1.34) |
| Region (ref = US Northeast) | |
| U.S. Midwest | 0.86 (0.75–0.98) |
| U.S. South | 0.86 (0.73–1.01) |
| U.S. West | 0.61 (0.51–0.73) |
| Non-U.S. | 1.05 (0.76–1.44) |
| Timing of cancer diagnosis (ref = Greater than 5 years prior to COVID-19 diagnosis) | |
| Within 1 year of COVID-19 diagnosis | 1.06 (0.91–1.24) |
| Between one and five years prior to COVID-19 diagnosis | 0.94 (0.82–1.09) |
| Interaction terms (ref = patients with nonrecently treated B-lymphoid malignancies in remission/NED) | |
| Negative control population x active and stable/responding cancer | 1.80 (1.16–2.80) |
| Positive control population x active and stable/responding cancer | 1.57 (1.16–2.12) |
| Patients recently treated for B-lymphoid malignancies x active and stable/responding cancer | 0.78 (0.46–1.31) |
| Negative control population x active and progressing cancer | 1.48 (0.70–3.10) |
| Positive control population x active and progressing cancer | 1.02 (0.71–1.46) |
| Patients recently treated for B-lymphoid malignancies x active and progressing cancer | 0.76 (0.38–1.54) |
| Negative control population x unknown cancer status | 1.94 (1.05–3.58) |
| Positive control populationx unknown cancer status | 1.69 (1.13–2.51) |
| Patients recently treated for B-lymphoid malignancies x unknown cancer status | 0.77 (0.36–1.64) |
NOTE: An OR > 1 indicates increased risk of high COVID-19 severity; Odds Ratio < 1 indicates decreased risk of high COVID-19 severity.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NED, no evidence of disease.